Status:
UNKNOWN
Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis
Lead Sponsor:
Medical University of Vienna
Conditions:
Pustular Palmoplantar Psoriasis
Eligibility:
All Genders
18-90 years
Phase:
PHASE3
Brief Summary
The purpose of this prospective, randomized, controlled, single-blinded investigation is to study the efficacy, tolerability and safety of oral photochemotherapy (PUVA) combined with acitretin versus ...
Detailed Description
Acitretin-PUVA treatment schedule: Acitretin monotherapy: Patients randomized to the acitretin group will receive acitretin in a dose of 1mg /kg daily two weeks prior to additional PUVA treatment. A...
Eligibility Criteria
Inclusion
- Patients with pustular palmoplantar psoriasis
- Patients older than 18 years
Exclusion
- Pregnant and lactating women
- Uncontrolled hyperlipidemia
- Patients with severely impaired hepatic function
- Patients with severely impaired renal function
- Immunosuppression.
- Abnormal UVA sensitivity
- Intake of photosensitizing drugs
- Oral antipsoriatic therapy within the last 4 weeks
- Topical antipsoriatic therapy within the last 2 weeks
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2010
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00811005
Start Date
October 1 2008
End Date
October 1 2010
Last Update
September 18 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna; University Clinic of Dermatology; Division of Special and Environmental Dermatology
Vienna, Vienna, Austria, 1180